Arizona State University/Halberd Corp. Covid-19 Research Program Progress - Successful Covid Spike Protein Disease Antigen Re-Creation!
Halberd Corporation (OTC PINK: HALB) announced a significant breakthrough in its COVID-19 research project with Arizona State University. Dr. Qiang Chen's team successfully recreated the coronavirus spike protein disease antigen, paving the way for the identification of proprietary antibodies expected within two weeks. The joint efforts aim to secure patent protections for their findings. The company's patented extracorporeal process could improve detection and treatment of COVID-19 while minimizing side effects associated with traditional drug therapies.
- Successful recreation of coronavirus spike protein antigen.
- Proprietary antibodies expected to be developed in two weeks.
- Joint patent application with Arizona State University.
- Potential therapeutic advantages of Halberd's extracorporeal process.
- None.
JACKSON CENTER, PA / ACCESSWIRE / September 21, 2020 / Halberd Corporation (OTC PINK:HALB) released a progress update on the research being conducted in conjunction with Arizona State University researchers. Dr. Qiang Chen, ASU's lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research.
With this breakthrough, Dr. Chen's team will immediately commence the identification of suitable antibodies. Dr. Chen expects to have proprietary antibodies within the next two weeks.
Patent attorneys will pursue immediate protection for joint Intellectual Property ownership by Arizona State University and Halberd Corporation.
William A. Hartman, Halberd Corporation Chairman, President & CEO, and the Halberd team of doctors, Patricio Reyes, Abdon Nanhay and Edson Brito, jointly report, "We conducted the first of a planned series of technology review meetings late last week and are very impressed with the progress Dr. Chen and his team are making on our project. We look forward to having spike protein antigen antibodies in two weeks so we can begin the next phase of development - creating suitable fluorescent antibody conjugates. Fluorescence is necessary for rapid detection and elimination of the coronavirus disease antigens via our patented extracorporeal process and related provisional patents. Halberd's patented extracorporeal process has the potential added therapeutic value of reducing or eliminating the chances of potentially dangerous side-effects associated with drugs administered internally."
The details of the Halberd/ASU research contract can be viewed here.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC
About Arizona State University.
Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona. It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.
About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Title | Application No. | Filing Date | Priority | Status |
Method for Treating and Curing Covid-19 Infection | US 62/989981 | 03/16/2020 | n/a | Provisional application Pending |
Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients | US 63/007207 | 04/08/2020 | n/a | Provisional application Pending |
Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus | US 63/013104 | 4/21/2020 | n/a | Provisional application Pending |
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/606926/Arizona-State-UniversityHalberd-Corp-Covid-19-Research-Program-Progress--Successful-Covid-Spike-Protein-Disease-Antigen-Re-Creation
FAQ
What is the recent development announced by Halberd Corporation regarding COVID-19?
When does Halberd expect to have proprietary antibodies ready?
What are the implications of Halberd's research progress for investors?
What is Halberd Corporation's stock symbol?
